Methamphetamine for Mood

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Chicago, Chicago, IL
Mood+1 More
Methamphetamine - Drug
Eligibility
18 - 65
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether marijuana can improve reward function in healthy young adults.

See full description

Eligible Conditions

  • Mood
  • Healthy Subjects (HS)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Methamphetamine will improve 1 primary outcome in patients with Mood. Measurement will happen over the course of Time Frame: Day 1(baseline), 3.

Day 1
Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ).

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Methamphetamine Then Placebo
1 of 2
Placebo Then Methamphetamine
1 of 2
Experimental Treatment

This trial requires 30 total participants across 2 different treatment groups

This trial involves 2 different treatments. Methamphetamine is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.

Methamphetamine Then PlaceboParticipants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.
Placebo Then MethamphetamineParticipants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2810
Metamfetamine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: time frame: day 1(baseline), 3
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly time frame: day 1(baseline), 3 for reporting.

Closest Location

University of Chicago - Chicago, IL

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There is one eligibility criterion to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
BMI between 19 and 26 Less than 4 alcohol or caffeinated beverages a day.

Patient Q&A Section

How many people get healthy subjects (hs) a year in the United States?

"Results from a recent paper support the need for an additional source of Hs in order to accurately monitor and measure the overall burden of disease. The use of existing Hs as a metric for the burden of disease may underestimate the total burden of disease if the Hs include a subset of individuals who are at risk for developing disease." - Anonymous Online Contributor

Unverified Answer

What are common treatments for healthy subjects (hs)?

"Common treatments include aspirin for dyslipidemia, statins, or fibrates. The use of antihypertensive medications is common but should be used cautiously because they may interact with warfarin and clopidogrel. These medications are not always used appropriately." - Anonymous Online Contributor

Unverified Answer

What are the signs of healthy subjects (hs)?

"- Healthy subjects (hs) are asymptomatic.\n- Healthy subjects (hs) are not able to discriminate between the different types of hand tools in the testing room.\n- Healthy subjects (hs) show better hand skill than do subjects with hand problems as evidenced by the fact that the former can finish the tests sooner.\n- Healthy subjects (hs) are able to draw more accurately than subjects with hand problems.\nThe hand performance of healthy subjects (hs) and subjects with hand problems does not differ in the test room environment, that is, healthy subjects (hs) can discriminate between tools." - Anonymous Online Contributor

Unverified Answer

What causes healthy subjects (hs)?

"The causes of healthy subjects are currently unknown. But, several factors have been associated with the development of healthy subjects in the past, including some factors, such as genetics, aging, smoking, physical activity, intake in the diet, and drugs or environmental toxicants. However, these factors may not contribute to explain, for example, about 65% of the variation in healthy subjects found in the United States." - Anonymous Online Contributor

Unverified Answer

What is healthy subjects (hs)?

"Hs represent a common and reproducible subpopulation of the general population that are considered to be a homogenous population as they share similar characteristics with regards to age, sex and socio-economical status. Thus, the results obtained in Hs represent the true pattern of human aging. Hs are a very important human model in the study of human aging, since they have minimal changes compared to the main features of human aging, such as age-related changes in the body." - Anonymous Online Contributor

Unverified Answer

Can healthy subjects (hs) be cured?

"Fungi (Candida albicans and Candida dubliniensis) had a low prevalence but a high recidivism rate in hs during oral candidiasis. Oral candidiasis is associated with symptomatic candidiasis at ages 3-6 weeks postnatally and is associated with thrush at 2 years of age. In hs, recidivism is low and symptoms are atypical." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating healthy subjects (hs)?

"Currently, there are no FDA-regulated drugs and therapies that have been approved specifically for treating healthy subjects. However, there are a few drugs and therapies that can treat multiple hs conditions. Additionally, there are several clinical trials that use a "healthy subjects plus" component, where participants who are not healthy are also included as subjects. More research has to be done in this area to determine if and how the safety and efficacy of these drugs and therapies can be evaluated and regulated." - Anonymous Online Contributor

Unverified Answer

Does methamphetamine improve quality of life for those with healthy subjects (hs)?

"Results from this study suggest that methamphetamine use is associated with improvements in some domains of QOL. These improvements in QOL are particularly pronounced in women and those with higher baseline levels of psychological distress; hence, methamphetamine use should be considered a possible treatment strategy when other drugs are not tolerated." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets healthy subjects (hs)?

"Healthy subjects are an average age 55. (https://www.endocrineonline.org/pages/about/pages/health.aspx) In the United States, the majority of people diagnosed with a disease are [older than 60 or younger than 18 (https://www.ende.ncts.gov/pub/beprogram/BPP/index.aspx)], and the average person getting healthy is more than 60 years. People getting healthy are also healthier. People getting healthy would be an hs-like age 55 for women and an hs-like age 40 for men." - Anonymous Online Contributor

Unverified Answer

How does methamphetamine work?

"The data support a model of METH being able to enhance dopamine transporter availability in the striatum, thereby increasing striatal DAT availability and releasing endogenous DA in the putamen and nucleus accumbens. Both the putamen and the caudate may be important for this action as the latter could mediate METH-induced euphoria and enhanced behavioral responses to cocaine. However, since plasma METH levels were similar to those found following previous intracranial METH use, these changes are likely to result from sustained, though not recurrent, use of METH rather than a direct effect of METH on the striatum or other brain regions." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for healthy subjects (hs)?

"[A cohort of patients undergoing clinical trials may have the potential to be representative for the general population of the country, and thus hs may be appropriate study groups for studies targeted to address the broadest range of research questions in general clinical research.] The general population may represent the population of interest to clinical trialists, the hs, and the patients." - Anonymous Online Contributor

Unverified Answer

Have there been other clinical trials involving methamphetamine?

"Methamphetamine use is likely common in both clinical trials and community-based studies. Methamphetamine may be a useful clinical probe to understand the nature of drug-induced cognitive change." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Mood by sharing your contact details with the study coordinator.